Hims & Hers Launches Generic Semaglutide in Canada at $149/Month
Event summary
- Hims & Hers now offers generic semaglutide in Canada starting at $149/month CAD for eligible customers.
- Health Canada authorized generic semaglutide, creating a more competitive GLP-1 market.
- The offering includes personalized care plans and ongoing access to Canadian healthcare providers.
- Nearly two-thirds of Canadian adults are overweight or obese, representing a significant market opportunity.
The big picture
Hims & Hers' move into generic semaglutide aligns with broader industry trends toward cost-effective obesity treatments. The launch could pressure incumbent providers to lower prices, expanding access for patients. With nearly two-thirds of Canadian adults overweight or obese, this represents a significant market opportunity for telehealth platforms.
What we're watching
- Market Competition
- Whether Hims & Hers can sustain pricing pressure as more providers enter the GLP-1 market.
- Regulatory Dynamics
- How Health Canada's approval of generic semaglutide will impact broader drug pricing policies.
- Customer Adoption
- The pace at which Canadians transition from branded to generic semaglutide treatments.
Related topics